Tagged with GE

Brazil Jun Eguti, general manager of Grünenthal Brazil, highlights the global transformation Grünenthal has undergone in the past two years, the huge potential the Brazilian affiliate has to become one of the largest in LatAm and the exciting product pipeline the affiliate has in Pain Management, Women’s Health, CNS and Gout…

India A strong advocate for quality, Dilip Surana, chairman and managing director of Micro Labs, explains how the company’s strong focus on the quality of its products and move to specialty generics has led them to success in both the Indian and US markets. When we met in 2011, the company…

Canada Dr. David Goodman, CEO of Pharmascience, talks about the strategy for the international expansion of the company, key for which are long-lasting partnerships. He also analyzes the re-organization of the company amongst the two main axes of generics and branded products and highlights its dedication to R&D, especially in the…

Poland Michał Mieszkowski, general manager of Angelini Poland, discusses the strategic significance of Poland for the company, as the third largest affiliate within the global company, the company’s impressive product portfolio and exciting pipeline, new therapeutic areas, and his future aspirations for Angelini Poland. As the general manager for Poland at…

India Amit Mookim, IQVIA’s general manager for South Asia, discusses the major trends impacting the Indian pharmaceutical market and how Indian companies are rethinking their commercial strategies and becoming more specialized to reach sophisticated international markets. Mr. Mookim, could you give our international readers a brief introduction of IQVIA and explain…

Poland Stefan Buguslawski, president of PEX Pharmasequence, a leading Polish healthcare consultancy and market research company, highlights the current obstacles facing the Polish healthcare market and the dynamics of the domestic pharmaceutical industry. He also discusses the innovative services they provide and how their offering will develop in the future. As…

Switzerland Dr. Raymond De Vré, senior VP and head of Business Operations and Strategy, Biologics at Dr. Reddy’s in Switzerland, discusses scaling up the Indian-headquartered company’s biosimilars business globally and the importance of selecting Switzerland as the location for regional headquarters.   The main challenge in the mature markets is the…

Poland Wojciech Sulimierski, general manager of Aspen Poland and CEE, discusses the opening of the regional operations in 2014 and the importance of the CEE region as the company establishes itself in the global pharmaceutical ecosystem. Moreover, he highlights the impact of global acquisitions and the niche area model they have…

Serbia Martin Knapp, managing director of the German Chamber of Commerce in Serbia, highlights how Serbia can further develop a more investment-friendly environment and the progress that the country has already made in this regard. Mr. Knapp, it is your second tenure as the Director of AHK in Serbia. What makes…

Canada Ian Jacobson, CEO of Juno Pharmaceuticals, presents the company’s business model of in-licensing and repurposing generic products. He highlights the successful development of the company’s affiliates in Australia, the UK and South Africa, and his plans to refocus efforts on the Canadian market in the near future, aiming to launch…

Lithuania Audrius Tutlys, country manager at Teva Lithuania, highlights the importance of Teva in Lithuania, based not only on its broad product offering but also its manufacturing capabilities and shares his willingness to position Teva as a true partner of the government in making Lithuania a European biotech center. Can you…

Canada Madhu Venkat, CEO of Natco Pharma Canada, highlights the company’s portfolio strategy, its strategic road map to be the first mover and become a leading generic supplier in oncology by 2020. He further illustrates that to be successful in Canada, it pays off to be a niche player and vertically…